<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f849b89b-f428-48c3-a779-463e444ec8ce"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20100604"/>
   <setId root="983ce15f-cd37-4f3a-9e51-205860e80976"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d122a094-7e3e-498f-80e5-a457a0b75734"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20100820"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-5889" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>OsmoPrep<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, SODIUM PHOSPHATE, DIBASIC ANHYDROUS</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="65649-701" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="1.102" unit="g"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="0.398" unit="g"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="32" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5889-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-5889-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080530"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021892" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SLX;102</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="f9561c5c-d6fd-4e27-b07d-e26b4fe3efc6"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <text>
                  <linkHtml href=""/>
                  <content styleCode="underline">WARNINGS</content>
                  <paragraph>There have been rare, but serious reports of acute phosphate 
nephropathy in patients who received oral sodium phosphate products for colon 
cleansing prior to colonoscopy. Some cases have resulted in permanent impairment 
of renal function and some patients required long-term dialysis. While some 
cases have occurred in patients without identifiable risk factors, patients at 
increased risk of acute phosphate nephropathy may include those with increased 
age, hypovolemia, increased bowel transit time (such as bowel obstruction), 
active colitis, or baseline kidney disease, and those using medicines that 
affect renal perfusion or function (such as diuretics, angiotensin converting 
enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly 
nonsteriodal anti-inflammatory drugs [NSAIDs]).<br/>
                     <content styleCode="italics">See 
</content>
                     <content styleCode="bold">
                        <linkHtml href="#d180fb29-7b1f-257f-ffb5-8bede3e82cb3">WARNINGS</linkHtml>
                     </content>.<br/>It is 
important to use the dose and dosing regimen as recommended (pm/am split 
dose).<br/>
                     <content styleCode="italics">See </content>
                     <content styleCode="bold">
                        <linkHtml href="#e471a662-8773-bd8d-8af8-06e0b569b807">DOSAGE and 
ADMINISTRATION</linkHtml>
                     </content>.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="f4f1f101-9301-4cf0-b250-4d59523b6954"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>OsmoPrep<sup>®</sup> (sodium phosphate monobasic 
monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) is a purgative 
used to clean the colon prior to colonoscopy. OsmoPrep is manufactured with a 
highly soluble tablet binder and does not contain microcrystalline cellulose 
(MCC). OsmoPrep Tablets are oval, white to off-white compressed tablets, 
debossed with “SLX” on one side of the bisect and “102” on the other side of the 
bisect. Each OsmoPrep tablet contains 1.102 grams of sodium phosphate monobasic 
monohydrate, USP and 0.398 grams of sodium phosphate dibasic anhydrous, USP for 
a total of 1.5 grams of sodium phosphate per tablet. Inert ingredients include 
polyethylene glycol 8000, NF; and magnesium stearate, NF. OsmoPrep is 
gluten-free.</paragraph>
                  <paragraph>The structural and molecular formulae and molecular weights of the active 
ingredients are shown below:</paragraph>
                  <list listType="unordered" ID="i48df2d13-a47a-4ded-88e4-73d6b454c8b0">
                     <item>Sodium phosphate monobasic monohydrate, USP<br/>Molecular Formula: NaH<sub>2</sub>PO<sub>4</sub> • H<sub>2</sub>O<br/>Molecular Weight: 137.99 <renderMultiMedia referencedObject="MM1"/>
                     </item>
                     <item>Sodium phosphate dibasic anhydrous, USP<br/>Molecular Formula: Na<sub>2</sub>HPO<sub>4</sub>
                        <br/>Molecular Weight: 141.96 <renderMultiMedia referencedObject="MM2"/>
                     </item>
                  </list>OsmoPrep Tablets are for oral administration only.</text>
               <effectiveTime value="20100604"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of chem structure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="chemical structure 1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>image of chem structure 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="chemical structure 2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e0eaad76-5e51-4305-803b-bc12861b396e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>OsmoPrep Tablets, a dosing regimen containing 48 grams of sodium 
phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire 
colon. Each administration has a purgative effect for approximately 1 to 3 
hours. The primary mode of action is thought to be through the osmotic effect of 
sodium, causing large amounts of water to be drawn into the colon, promoting 
evacuation.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Pharmacokinetics<paragraph>Pharmacokinetic studies with OsmoPrep have not been conducted. 
However, the following pharmacokinetic study was conducted with Visicol® tablets 
which contain the same active ingredients (sodium phosphate) as OsmoPrep. In 
addition, Visicol is administered at a dose that is 25% greater than the 
OsmoPrep dose.</paragraph>
                  <paragraph>An open-label pharmacokinetic study of Visicol in healthy volunteers was 
performed to determine the concentration-time profile of serum inorganic 
phosphorus levels after Visicol administration. All subjects received the 
approved Visicol dosing regimen (60 grams of sodium phosphate with a total 
liquid volume of 3.6 quarts) for colon cleansing. A 30 gram dose (20 tablets 
given as 3 tablets every 15 minutes with 8 ounces of clear liquids) was given 
beginning at 6 PM in the evening. The 30 gram dose (20 tablets given as 3 
tablets every 15 minutes with 8 ounces of clear liquids) was repeated the 
following morning beginning at 6 AM.</paragraph>
                  <paragraph>Twenty-three healthy subjects (mean age 57 years old; 57% male and 43% 
female; and 65% Hispanic, 30% Caucasian, and 4% African-American) participated 
in this pharmacokinetic study. The serum phosphorus level rose from a mean (± 
standard deviation) baseline of 4.0 (± 0.7) mg/dL to 7.7 (± 1.6 mg/dL), at a 
median of 3 hours after the administration of the first 30-gram dose of sodium 
phosphate tablets (see <linkHtml href="#section-">  Figure 1</linkHtml>). The serum phosphorus level 
rose to a mean of 8.4 (± 1.9) mg/dL, at a median of 4 hours after the 
administration of the second 30-gram dose of sodium phosphate tablets. The serum 
phosphorus level remained above baseline for a median of 24 hours after the 
administration of the initial dose of sodium phosphate tablets (range 16 to 48 
hours).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1. Mean (± standard deviation) serum phosphorus 
concentrations</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>The upper (4.5 mg/dL) and lower (2.6 mg/dL) reference limits for serum 
phosphate are represented by solid bars.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>Special Populations<linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <paragraph>
                     <content styleCode="bold">Renal Insufficiency:</content> The effect of renal 
dysfunction on the pharmacokinetics of OsmoPrep Tablets has not been studied. 
Since the inorganic form of phosphate in the circulating plasma is excreted 
almost entirely by the kidneys, patients with renal disease may have difficulty 
excreting a large phosphate load. Thus, OsmoPrep Tablets should be used with 
caution in patients with impaired renal function (see <linkHtml href="#section-"> WARNINGS</linkHtml>).</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <paragraph>
                     <content styleCode="bold">Hepatic Insufficiency:</content> OsmoPrep Tablets 
have not been investigated in patients with hepatic failure.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <paragraph>
                     <content styleCode="bold">Geriatric:</content> In a single pharmacokinetic 
study of sodium phosphate tablets, which included 6 elderly volunteers, plasma 
half-life increased two-fold in subjects greater than 70 years of age compared to 
subjects less than 50 years of age (3 subjects and 5 subjects, respectively).</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <paragraph>
                     <content styleCode="bold">Gender:</content> No difference in serum phosphate 
AUC values were observed in the single pharmacokinetic study conducted with 
sodium phosphate tablets in 13 male and 10 female healthy volunteers. </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20100604"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM3">
                     <text>image of figure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="figure 1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4d890f5c-1d0e-4135-b8b8-012bbac67d27"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <text>
                  <paragraph>The colon cleansing efficacy and safety of OsmoPrep was evaluated 
in 2 randomized, investigator-blinded, actively controlled, multicenter, U.S. 
trials in patients scheduled to have an elective colonoscopy. The trials 
consisted of a dose ranging and a confirmatory phase 3 study.</paragraph>
                  <paragraph>In the phase 3 trial, patients were randomized into one of the following 
three sodium phosphate treatment groups: 1) Visicol containing 60 grams of 
sodium phosphate given in split doses (30 grams in the evening before the 
colonoscopy and 30 grams on the next day) with at least 3.6 quarts of clear 
liquids; 2) OsmoPrep containing 60 grams of sodium phosphate given in split 
doses (30 grams in the evening before the colonoscopy and 30 grams on the next 
day) with 2.5 quarts of clear liquids; and 3) OsmoPrep containing 48 grams of 
sodium phosphate (30 grams in the evening before the colonoscopy and 18 grams on 
the next day) with 2 quarts of clear liquids. Patients were instructed to eat a 
light breakfast before noon on the day prior to the colonoscopy and then were 
told to drink only clear liquids after noon on the day prior to the 
colonoscopy.</paragraph>
                  <paragraph>The primary efficacy endpoint was the overall colon cleansing response rate 
in the 4-point Colonic Contents Scale. Response was defined as a rating of 
“excellent” or “good” on the 4-point scale as determined by the blinded 
colonoscopist. This phase 3 study was planned to assess the non-inferiority of 
the two OsmoPrep groups compared to the Visicol group.</paragraph>
                  <paragraph>The efficacy analysis included 704 adult patients who had an elective 
colonoscopy. Patients ranged in age from 21 to 89 years old (mean age 56 years 
old) with 55% female and 45% male patients. Race was distributed as follows: 87% 
Caucasian, 10% African American, and 3% other race. The OsmoPrep 60 gram and 48 
gram treatment groups demonstrated non-inferiority compared to Visicol. See 
Table 1 for the results.</paragraph>
                  <table width="100%" ID="i194ffd24-3044-4397-894f-c65a4d73c31f">
                     <caption>Table 1: Phase 3 Study – Overall Colon Content Cleansing Response Rates1</caption>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Treatment Arm<br/>(grams of sodium<br/>phosphate)<br/>
                              </content>
                           </td>
                           <td>
                              <content styleCode="bold">No. of tablets taken at<br/>6 PM on the day prior<br/>to colonoscopy<br/>
                              </content>
                           </td>
                           <td>
                              <content styleCode="bold">No. of tablets<br/>taken the next<br/>day<sup>2</sup>
                                 <br/>
                              </content>
                           </td>
                           <td>
                              <content styleCode="bold">Excellent</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Good</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Fair</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Inadequate</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Overall Response<br/>Rate (Excellent or Good)<br/>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td>OsmoPrep<br/>32 tabs (48 g)<br/>n = 236<br/>
                           </td>
                           <td>20<br/>
                           </td>
                           <td>12<br/>
                           </td>
                           <td>76%<br/>
                           </td>
                           <td>19%<br/>
                           </td>
                           <td>3%<br/>
                           </td>
                           <td>2%<br/>
                           </td>
                           <td>95%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>OsmoPrep<br/>40 tabs (60 g)<br/>n = 233<br/>
                           </td>
                           <td>20<br/>
                           </td>
                           <td>20<br/>
                           </td>
                           <td>73%<br/>
                           </td>
                           <td>24%<br/>
                           </td>
                           <td>2%<br/>
                           </td>
                           <td>1%<br/>
                           </td>
                           <td>97%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Visicol<br/>40 tabs (60 g)<br/>n = 235<br/>
                           </td>
                           <td>20<br/>
                           </td>
                           <td>20<br/>
                           </td>
                           <td>51%<br/>
                           </td>
                           <td>43%<br/>
                           </td>
                           <td>6%<br/>
                           </td>
                           <td>0%<br/>
                           </td>
                           <td>94%<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <sup>1</sup>  Colon-cleansing efficacy was based on response rate to treatment. A patient was 
considered to be a responder if overall colon cleansing was rated as “excellent” 
or “good” on a 4-point scale based on the amount of retained “colonic contents.” 
Excellent was defined as greater than 90% of mucosa seen, mostly liquid stool, minimal 
suctioning needed for adequate visualization. Good was defined as greater than 90% of 
mucosa seen, mostly liquid stool, significant suctioning needed for adequate 
visualization. Fair was defined as greater than 90% of mucosa seen, mixture of liquid and 
semisolid stool, could be suctioned and/or washed. Inadequate was defined as 
less than 90% of mucosa seen, mixture of semisolid and solid stool which could not be 
suctioned or washed.<br/>
                  <sup>2</sup>  On the day of the colonoscopy, study medication was taken 3 to 5 hours before the 
start of the colonoscopy.<br/>
                  <br/>the day of the colonoscopy, study medication was taken 3 to 5 hours before the 
start of the colonoscopy.<br/>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3c73d3eb-8239-4a0d-8c23-4e3674c7b774"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>OsmoPrep Tablets are indicated for cleansing of the colon as a 
preparation for colonoscopy in adults 18 years of age or older.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ed6953c4-6af4-429c-a46f-86c4b2db6e3d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>OsmoPrep Tablets are contraindicated in patients with 
biopsy-proven acute phosphate nephropathy. </paragraph>
                  <paragraph>OsmoPrep Tablets are contraindicated in patients with a known allergy or 
hypersensitivity to sodium phosphate salts or any of its ingredients.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5a0b52fb-64be-40ab-ac17-9903dbac1e13"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Administration of sodium phosphate products prior to colonoscopy 
for colon cleansing has resulted in fatalities due to significant fluid shifts, 
severe electrolyte abnormalities, and cardiac arrhythmias. These fatalities have 
been observed in patients with renal insufficiency, in patients with bowel 
perforation, and in patients who misused or overdosed sodium phosphate products. 
It is recommended that patients receiving OsmoPrep be advised to adequately 
hydrate before, during, and after the use of OsmoPrep.</paragraph>
                  <paragraph>Considerable caution should be advised before OsmoPrep Tablets are used in 
patients with the following illnesses: severe renal insufficiency (creatinine 
clearance less than 30 mL/minute), congestive heart failure, ascites, unstable 
angina, gastric retention, ileus, acute bowel obstruction, pseudo-obstruction of 
the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic 
megacolon, gastric bypass or stapling surgery, or hypomotility syndrome.</paragraph>
                  <paragraph>Consider performing baseline and post-colonoscopy labs (phosphate, calcium, 
potassium, sodium, creatinine, and BUN) in patients who may be at increased risk 
for serious adverse events, including those with history of renal insufficiency, 
history of-or at greater risk of-acute phosphate nephropathy, known or suspected 
electrolyte disorders, seizures, arrhythmias, cardiomyopathy, prolonged QT, 
recent history of a MI and those with known or suspected hyperphosphatemia, 
hypocalcemia, hypokalemia, and hypernatremia. Also if patients develop vomiting 
and/or signs of dehydration then measure post-colonoscopy labs (phosphate, 
calcium, potassium, sodium, creatinine, and BUN).</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Renal Disease, Acute Phosphate Nephropathy, and 
Electrolyte Disorders<paragraph>There have been rare, but serious, reports of renal failure, 
acute phosphate nephropathy, and nephrocalcinosis in patients who received oral 
sodium phosphate products (including oral sodium phosphate solutions and 
tablets) for colon cleansing prior to colonoscopy. These cases often resulted in 
permanent impairment of renal function and several patients required long-term 
dialysis. The time to onset is typically within days; however, in some cases, 
the diagnosis of these events has been delayed up to several months after the 
ingestion of these products. Patients at increased risk of acute phosphate 
nephropathy may include patients with the following: hypovolemia, baseline 
kidney disease, increased age, and patients using medicines that affect renal 
perfusion or function [such as diuretics, angiotensin converting enzyme 
(ACE)inhibitors, angiotensin receptor blockers, and possibly nonsteroidal 
anti-inflammatory drugs (NSAIDs).</paragraph>
                  <paragraph>Use OsmoPrep with caution in patients with impaired renal function, patients 
with a history of acute phosphate nephropathy, known or suspected electrolyte 
disturbances (such as dehydration), or people taking concomitant medications 
that may affect electrolyte levels (such as diuretics). Patients with 
electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, 
or hypocalcemia should have their electrolytes corrected before treatment with 
OsmoPrep Tablets.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Seizures<paragraph>There have been rare reports of generalized tonic-clonic seizures 
and/or loss of consciousness associated with use of sodium phosphate products in 
patients with no prior history of seizures. The seizure cases were associated 
with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, 
and hypomagnesemia) and low serum osmolality. The neurologic abnormalities 
resolved with correction of fluid and electrolyte abnormalities. OsmoPrep should 
be used with caution in patients with a history of seizures and in patients at 
higher risk of seizure [patients using concomitant medications that lower the 
seizure threshold (such as tricyclic antidepressants), patients withdrawing from 
alcohol or benzodiazepines, or patients with known or suspected 
hyponatremia].</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Cardiac Arrhythmias<paragraph>There have been rare, but serious, reports of arrhythmias 
associated with the use of sodium phosphate products. OsmoPrep should be used 
with caution in patients with higher risk of arrhythmias (patients with a 
history of cardiomyopathy, patients with prolonged QT, patients with a history 
of uncontrolled arrhythmias, and patients with a recent history of a myocardial 
infarction). Pre-dose and post-colonoscopy ECGs should be considered in patients 
with high risk of serious, cardiac arrhythmias.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e5e3d424-457d-49a3-beee-131b30589d89"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <linkHtml href=""/>General<paragraph>Patients should be instructed to drink 8 ounces of clear liquids 
with each 4-tablet dose of OsmoPrep Tablets. Patients should take a total of 2 
quarts of clear liquids with OsmoPrep. Inadequate fluid intake, as with any 
effective purgative, may lead to excessive fluid loss, hypovolemia, and 
dehydration. Dehydration from purgation may be exacerbated by inadequate oral 
fluid intake, vomiting, and/or use of diuretics.</paragraph>
                  <paragraph>Patients should be instructed not to administer additional laxative or 
purgative agents, particularly additional sodium phosphate-based purgative or 
enema products.</paragraph>
                  <paragraph>Prolongation of the QT interval has been observed in some patients who were 
dosed with sodium phosphate colon preparations. QT prolongation with sodium 
phosphate tablets has been associated with electrolyte imbalances, such as 
hypokalemia and hypocalcemia. OsmoPrep Tablets should be used with caution in 
patients who are taking medications known to prolong the QT interval, since 
serious complications may occur. Pre-dose and post-colonoscopy ECGs should be 
considered in patients with known prolonged QT.</paragraph>
                  <paragraph>Administration of OsmoPrep Tablets may induce colonic mucosal aphthous 
ulcerations, since this endoscopic finding was observed with other sodium 
phosphate cathartic preparations. In the OsmoPrep clinical program, aphthous 
ulcers were observed in 3% of patients who took the 48 gram OsmoPrep dosing 
regimen. This colonoscopic finding should be considered in patients with known 
or suspected inflammatory bowel disease.</paragraph>
                  <paragraph>Because published data suggest that sodium phosphate absorption may be 
enhanced in patients experiencing an acute exacerbation of chronic inflammatory 
bowel disease, OsmoPrep Tablets should be used with caution in such 
patients.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Drug Interactions<paragraph>Medications administered in close proximity to OsmoPrep Tablets 
may not be absorbed from the gastrointestinal tract due to the rapid intestinal 
peristalsis and watery diarrhea induced by the purgative agent.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<paragraph>Long-term studies in animals have not been performed to evaluate 
the carcinogenic potential of OsmoPrep. Studies to evaluate the effect of 
OsmoPrep on fertility or its mutagenic potential have not been performed.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">Pregnancy. Teratogenic Effects: 
Pregnancy Category C</content>
                  <paragraph>Animal reproduction studies have not been conducted with 
OsmoPrep. It is not known whether OsmoPrep can cause fetal harm when 
administered to a pregnant woman, or can affect reproduction capacity. OsmoPrep 
Tablets should be given to a pregnant woman only if clearly needed.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Pediatric Use<paragraph>The safety and efficacy of OsmoPrep Tablets have not been 
demonstrated in patients less than 18 years of age.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>Geriatric Use<paragraph>In controlled colon preparation trials of OsmoPrep, 228 (24%) of 
931 patients were 65 years of age or older. In addition, 49 (5%) of the 931 
patients were 75 years of age or older.</paragraph>
                  <paragraph>Of the 228 geriatric patients in the trials, 134 patients (59%) received at 
least 48 grams of OsmoPrep. Of the 49 patients 75 years old or older in the 
trials, 27 (55%) patients received at least 48 grams of OsmoPrep.  No overall 
differences in safety or effectiveness were observed between geriatric patients 
and younger patients. However, the mean phosphate levels in geriatric patients 
were greater than the phosphate levels in younger patients after OsmoPrep 
administration. The mean colonoscopy-day phosphate levels in patients 18-64, 
65-74, and ≥ 75 years old who received 48 grams of OsmoPrep in the phase 3 study 
were 7.0, 7.3, and 8.0 mg/dL, respectively. In addition, in all three sodium 
phosphate treatment groups, the mean phosphate levels in patients 18-64, 65-74, 
and ≥ 75 years old in the phase 3 study were 7.4, 7.9, and 8.0 mg/dL, 
respectively, after sodium phosphate administration. Greater sensitivity of some 
older individuals cannot be ruled out; therefore, OsmoPrep Tablets should be 
used with caution in geriatric patients.</paragraph>
                  <paragraph>Sodium phosphate is known to be substantially excreted by the kidney, and the 
risk of adverse reactions with sodium phosphate may be greater in patients with 
impaired renal function. Since geriatric patients are more likely to have 
impaired renal function, consider performing baseline and post-colonoscopy labs 
(phosphate, calcium, potassium, sodium, creatinine, and BUN) in these patients 
(see <linkHtml href="#d180fb29-7b1f-257f-ffb5-8bede3e82cb3">WARNINGS</linkHtml>). It is 
recommended that patients receiving OsmoPrep be advised to adequately hydrate 
before, during, and after the use of OsmoPrep.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ee3d3c4a-de11-4e1d-8da5-1b1411c48dab"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Abdominal bloating, abdominal pain, nausea, and vomiting were the 
most common adverse events reported with the use of OsmoPrep Tablets. Dizziness 
and headache were reported less frequently. Since diarrhea was considered as a 
part of the efficacy of OsmoPrep, diarrhea was not defined as an adverse event 
in the clinical studies. Table 2 shows the most common adverse events associated 
with the use of 48 grams of OsmoPrep, 60 grams of OsmoPrep, and 60 grams of 
Visicol in the colon preparation trials (n=931). </paragraph>
                  <table ID="idcf225b4-0a74-4b08-8e5c-b39af4ee4c4d">
                     <thead>
                        <tr>
                           <td>
                              <content styleCode="bold">Table 2: Frequency 
of Adverse Events of Any Severity<br/>Occurring in Greater Than 3% of Patients in 
the OsmoPrep<br/>Trials</content>
                           </td>
                        </tr>
                        <tr>
                           <th> </th>
                           <th>OsmoPrep <br/>32 tabs (48 g)<br/>N=272</th>
                           <th>OsmoPrep<br/>40 tabs (60 g)<br/>N=265</th>
                           <th>Visicol<br/>40 tabs (60 g)<br/>N=268</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td>Bloating</td>
                           <td>31%</td>
                           <td>39%</td>
                           <td>41%</td>
                        </tr>
                        <tr>
                           <td>Nausea</td>
                           <td>26%</td>
                           <td>37%</td>
                           <td>30%</td>
                        </tr>
                        <tr>
                           <td>Abdominal Pain</td>
                           <td>23%</td>
                           <td>24%</td>
                           <td>25%</td>
                        </tr>
                        <tr>
                           <td>Vomiting</td>
                           <td>4%</td>
                           <td>10%</td>
                           <td>9%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Postmarketing Experience</content>
                  </paragraph>
                  <paragraph>In addition to adverse events reported from clinical trials, the following 
adverse events have been identified during post-approval use of OsmoPrep. 
Because they are reported voluntarily from a population of unknown size, 
estimates of frequency cannot be made. These events have been chosen for 
inclusion due to either their seriousness, frequency of reporting or causal 
connection to OsmoPrep, or a combination of these factors.</paragraph>
                  <paragraph>
                     <content styleCode="bold">General: </content>Hypersensitivity reactions including 
anaphylaxis, rash, pruritus, urticaria, throat tightness, bronchospasm, dyspnea, 
pharyngeal edema, dysphagia, paresthesia and swelling of the lips and tongue, 
and facial swelling. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular:</content> Arrhythmias</paragraph>
                  <paragraph>
                     <content styleCode="bold">Nervous system: </content>Seizures</paragraph>
                  <paragraph>
                     <content styleCode="bold">Renal: </content>Renal impairment, increased blood urea 
nitrogen (BUN), increased creatinine, acute renal failure, acute phosphate 
nephropathy, nephrocalcinosis, and renal tubular necrosis.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="efc93787-1edf-4afc-af53-04055beb3532"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph>Laxatives and purgatives (including OsmoPrep) have the potential for abuse by 
bulimia nervosa patients who frequently have binge eating and vomiting.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="22078b90-2143-4441-bac4-e27c308b1996"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>There have been no reported cases of overdosage with OsmoPrep Tablets. 
Purposeful or accidental ingestion of more than the recommended dosage of 
OsmoPrep Tablets might be expected to lead to severe electrolyte disturbances, 
including hyperphosphatemia, hypocalcemia, hypernatremia, or hypokalemia, as 
well as dehydration and hypovolemia, with attendant signs and symptoms of these 
disturbances. Certain severe electrolyte disturbances resulting from overdose 
may lead to cardiac arrhythmias, seizure, renal failure, and death. The patient 
who has taken an overdosage should be monitored carefully, and treated 
symptomatically for complications until stable.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fd68c5d7-e662-4d63-9527-3d16982b87f8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dose of OsmoPrep Tablets for colon cleansing for 
adult patients is 32 tablets (48 grams of sodium phosphate) taken orally with a 
total of 2 quarts of clear liquids in the following manner:</paragraph> <content styleCode="bold">The evening before the colonoscopy procedure: </content>Take 4 
OsmoPrep Tablets with 8 ounces of clear liquids every 15 minutes for a total of 
20 tablets. <br/>
                  <br/> <content styleCode="bold">On the day of the colonoscopy procedure: </content>Starting 
3-5 hours before the procedure, take 4 OsmoPrep Tablets with 8 ounces of clear 
liquids every 15 minutes for a total of 12 tablets.<paragraph>Patients should be advised of the importance of taking the recommended fluid 
regimen. It is recommended that patients receiving OsmoPrep be advised to 
adequately hydrate before, during, and after the use of OsmoPrep.</paragraph>
                  <paragraph>Patients should not use OsmoPrep for colon cleansing within seven days of 
previous administration. No additional enema or laxative is required, and 
patients should be advised NOT to take additional agents, particularly those 
containing sodium phosphate.</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="1e065555-a8ea-45ac-82ec-c0443f309d84"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>OsmoPrep Tablets are supplied in child-resistant bottles 
containing 32 tablets. Each tablet contains 1.102 g sodium phosphate monobasic 
monohydrate, USP and 0.398 g sodium phosphate dibasic anhydrous, USP for a total 
of 1.5 g of sodium phosphate per tablet.</paragraph>
                  <table width="30%" ID="i00cfa7ab-a020-4283-87eb-f3f4c4f2f491">
                     <tbody>
                        <tr>
                           <td>NDC 54868-5889-1<br/>
                           </td>
                           <td>Bottles of 04<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>NDC 54868-5889-0<br/>
                           </td>
                           <td>Bottles of 32<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only.</content>
                  </paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP 
Controlled Room Temperature]. Discard any unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>WellSpring Pharmaceutical Canada 
Corp. <br/>Oakville, Ontario Canada L6H 1M5<br/>
                     <content styleCode="bold">for:</content>
                     <br/>Salix Pharmaceuticals, Inc. <br/>Morrisville, NC 27560 <br/>Made in Canada</paragraph>
                  <paragraph>VENART-30-4/Mar. 2009</paragraph>
                  <paragraph>Product protected by US Patent No. 5,616,346 and other pending applications.</paragraph>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Relabeling and Repackaging by:</content>
                     <br/>Physicians Total Care, Inc.<br/>Tulsa, OK     74146<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100820"/>
            </section>
         </component>
         <component>
            <section>
               <id root="253a2e63-a024-480b-bc41-cd5725e47317"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <linkHtml href=""/>Medication Guide<paragraph>
                     <content styleCode="bold">OsmoPrep</content>
                     <sup>®</sup>
                     <content styleCode="bold"> (AhZ-MŌ-prěp)</content> (sodium phosphate monobasic monohydrate, USP 
and sodium phosphate dibasic anhydrous, USP) Tablets </paragraph>
                  <paragraph>Read the Medication Guide that comes with OsmoPrep before you take it and 
each time you take it. This Medication Guide does not take the place of talking 
with your doctor about your medical condition or your treatment. If you have any 
questions about OsmoPrep, ask your doctor or pharmacist.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What is the most important 
information I should know about OsmoPrep?</content>
                  <paragraph>OsmoPrep can cause serious side effects, including:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious kidney problems.</content> Rare, but serious kidney 
problems can happen in people who take medicines made with sodium phosphate, 
including OsmoPrep, to clean your colon before colonoscopy. These kidney 
problems can sometimes lead to kidney failure or the need for dialysis for a 
long time. These problems often happen within a few days, but sometimes may 
happen several months after taking OsmoPrep.  </paragraph>
                  <paragraph>Conditions that can make you more at risk for having serious kidney problems 
with OsmoPrep include if you: </paragraph>
                  <list listType="unordered" ID="ief9a3dfe-f6bc-48de-8a60-1b256704aeba">
                     <item>lose too much body fluid (dehydration)</item>
                     <item>have slow moving bowels </item>
                     <item>have bowels blocked with stool (constipation)</item>
                     <item>have severe stomach pain or bloating</item>
                     <item>have any disease that causes bowel irritation (colitis)</item>
                     <item>have kidney disease</item>
                     <item>have heart failure</item>
                     <item>take water pills or non-steroidal anti-inflammatory drugs (NSAIDS)</item>
                  </list>
                  <paragraph>Your age may also affect your risk for having kidney problems with 
OsmoPrep.</paragraph>
                  <paragraph>Before you start taking OsmoPrep tell your doctor if you:</paragraph>
                  <list listType="unordered" ID="ic0b30fd7-d654-47c3-821b-da29197ec604">
                     <item>have kidney problems.</item>
                     <item>take any medicines for blood pressure, heart disease, or kidney 
disease.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Severe fluid loss.</content> People who take medicines that 
contain sodium phosphate can have severe loss of body fluid, with severe changes 
in body salts in the blood, and abnormal heart rhythms. These problems can lead 
to death.</paragraph>
                  <paragraph>Tell your doctor if you have any of these symptoms of loss of too much body 
fluid (dehydration) while taking OsmoPrep:</paragraph>
                  <list listType="unordered" ID="i74f9546d-43e0-4e0d-8aa7-1dbf0f4345a7">
                     <item>vomiting</item>
                     <item>dizziness </item>
                     <item>urinating less often than normal</item>
                     <item>headache</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">See “What are the possible side effects of OsmoPrep?” for 
more information about side effects.</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What is OsmoPrep?</content>
                  <br/>
                  <paragraph>OsmoPrep is a prescription medicine used in adults 18 years and 
older, to clean your colon before a colonoscopy. OsmoPrep cleans your colon by 
causing you to have diarrhea.  Cleaning your colon helps your doctor see the 
inside of your colon more clearly during the colonoscopy.</paragraph>
                  <paragraph>It is not known if OsmoPrep is safe and works in children under age 18.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">Who should not take OsmoPrep?</content>
                  <br/>Do not take OsmoPrep if:
<list listType="unordered" ID="id4e8b531-cd66-4ebf-8304-0d50e329f56e">
                     <item>you have had a kidney biopsy that shows you have kidney problems because of 
too much phosphate </item>
                     <item>you are allergic to sodium phosphate salts or any of the ingredients in 
OsmoPrep. See the end of this Medication Guide for a list of ingredients in 
OsmoPrep.</item>
                  </list>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What should I tell my doctor before 
taking OsmoPrep?</content>
                  <br/>Before taking OsmoPrep, tell your doctor about 
all of your medical conditions, including if you have: 
<list listType="unordered" ID="i3a22ddd5-af1c-4319-8842-32d26ae12ddf">
                     <item>any of the medical conditions listed in the section “What is the most 
important information I should know about OsmoPrep?"</item>
                     <item>irritation of the bowel (colitis). OsmoPrep can cause symptoms of irritable 
bowel disease to flare-up.</item>
                     <item>damage to your bowels</item>
                     <item>problems with abnormal heart beat </item>
                     <item>had a recent heart attack or have other heart problems</item>
                     <item>symptoms of too much body fluid loss (dehydration) including vomiting, 
dizziness, urinating less often than normal, or headache)</item>
                     <item>had stomach surgery</item>
                     <item>a history of seizures</item>
                     <item>if you drink alcohol</item>
                     <item>are on a low salt diet</item>
                     <item>are pregnant. It is not known if OsmoPrep will harm your unborn 
baby.</item>
                  </list>
                  <paragraph>Tell your doctor about all the medicines you take, including 
prescription and non-prescription medicines, vitamins, and herbal supplements. 
Any medicine that you take close to the time that you take OsmoPrep may not work 
as well. Especially tell your doctor if you take:</paragraph>
                  <list listType="unordered" ID="idf6c01d0-2f21-4386-806e-c720867a38d8">
                     <item>water pills (diuretics) </item>
                     <item>medicines for blood pressure or heart problems</item>
                     <item>medicines for kidney damage </item>
                     <item>medicines for pain, such as aspirin or a non-steroidal anti-inflammatory 
drug (NSAID)</item>
                     <item>a medicine for seizures</item>
                     <item>a laxative for constipation in the last 7 days. You should not take another 
medicine that contains sodium phosphate while you take OsmoPrep.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Ask your doctor if you are not sure if your medicine is 
listed above.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Know the medicines you take. Keep a list of your medicines 
to show your doctor or pharmacist when you get a new prescription.</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">How should I take OsmoPrep?</content>
                  <list listType="unordered" ID="iad036efd-93a6-4e76-8192-0e9b83f1401e">
                     <item>Take OsmoPrep exactly as prescribed by your doctor.</item>
                     <item>
                        <content styleCode="bold">It is important for you to drink clear liquids before, 
during, and after taking OsmoPrep. This may help prevent kidney damage.</content> 
Examples of <content styleCode="bold">clear liquids</content> are water, flavored water, 
lemonade (no pulp), ginger ale or apple juice. Do not drink any liquids colored 
purple or red. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">You must read, understand, and follow these 
instructions to take OsmoPrep the right way:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">On the evening before your colonoscopy</content> you will take 
a total of 20 OsmoPrep tablets, as follows:    </paragraph>
                  <list listType="ordered" ID="i8aca3332-0731-420f-834b-c5d3a492d038">
                     <item>Take 4 OsmoPrep tablets with 8 ounces of <content styleCode="bold">clear 
liquids.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Wait 15 minutes.</content>
                     </item>
                     <item>Take 4 more OsmoPrep tablets with 8 ounces of <content styleCode="bold">clear 
liquids.</content>
                     </item>
                     <item>Repeat steps 2 and 3 above, three more times. Make sure you wait 15 minutes 
after each time.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">On the day of your colonoscopy</content> you will take a total 
of 12 OsmoPrep tablets, starting about 3 to 5 hours before your colonoscopy, as 
follows:  </paragraph>
                  <list listType="ordered" ID="i3de9d064-b509-4461-89e0-9d9a6c60e6e5">
                     <item>Take 4 OsmoPrep tablets with 8 ounces of <content styleCode="bold">clear 
liquids.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Wait 15 minutes.</content>
                     </item>
                     <item>Take 4 more OsmoPrep tablets with 8 ounces of <content styleCode="bold">clear 
liquids.</content>
                     </item>
                     <item>Repeat steps 2 and 3 one more time.</item>
                  </list>
                  <paragraph>Tell your doctor if you have any of these symptoms while taking OsmoPrep: 
</paragraph>
                  <list listType="unordered" ID="i1bed018e-e60d-4bd6-81ca-c82585d994f3">
                     <item>vomiting, dizziness, or if you urinate less often than normal. These may be 
signs that you have lost too much fluid while taking OsmoPrep.</item>
                     <item>trouble drinking clear fluids</item>
                     <item>severe stomach cramping, bloating, nausea, or headache.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">If you take too much OsmoPrep, call your doctor or get 
medical help right away.</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What should I avoid while taking 
OsmoPrep?</content>
                  <list listType="unordered" ID="i697c8f2d-ec74-478d-831f-947a2ec12eaf">
                     <item>You should not take other laxatives or enemas made with sodium phosphate, 
while taking OsmoPrep. </item>
                     <item>You should not use OsmoPrep if you have already used it in the last 7 
days.</item>
                  </list>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What are the possible side effects 
of OsmoPrep?</content>
                  <paragraph>OsmoPrep can cause serious side effects, including:</paragraph> 
<list listType="unordered" ID="i0f3232c4-3b3d-4886-8c5c-1c1b54d20b05">
                     <item>See “What is the most important information I should know about OsmoPrep?” 
</item>
                     <item>Seizures or fainting (black-outs). People who take a medicine that contains 
sodium phosphate, such as OsmoPrep, can have seizures or faint (become 
unconscious) even if they have not had seizures before. Tell your doctor right 
away if you have a seizure or faint while taking OsmoPrep</item>
                     <item>Abnormal heart beat (arrhythmias)</item>
                     <item>changes in your blood levels of calcium, phosphate, potassium, 
sodium</item>
                  </list>
                  <paragraph>The most common side effects of OsmoPrep are: </paragraph>
                  <list listType="unordered" ID="i6b338c98-1c42-491b-846a-ff7ec373d65e">
                     <item>bloating</item>
                     <item>stomach area (abdominal) pain</item>
                     <item>nausea</item>
                     <item>vomiting</item>
                  </list>
                  <paragraph>These are not all the possible side effects of OsmoPrep. For more 
information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side 
effects to FDA at 1-800-FDA-1088.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">How do I store OsmoPrep?</content>
                  <list listType="unordered" ID="i6a8727bf-164c-466f-8bf5-315905dc7089">
                     <item>Store OsmoPrep at room temperature, between 59° F to 86° F (15° C to 30° 
C).</item>
                     <item>Throw away any OsmoPrep that is not needed.</item>
                     <item>
                        <content styleCode="bold">Keep OsmoPrep and all medicines out of the reach of 
children.</content>
                     </item>
                  </list>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">General information about 
OsmoPrep</content>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those 
listed in a Medication Guide. Do not use OsmoPrep for a condition for which it 
was not prescribed. Do not give OsmoPrep to other people, even if they have the 
same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>This Medication Guide summarizes the most important information about 
OsmoPrep. If you would like more information about OsmoPrep, talk with your 
doctor or pharmacist. You can ask your doctor or pharmacist for information that 
is written for healthcare professionals. For more information, call 
1-866-669-7597 (toll-free) or go to <content styleCode="underline">
                        <content styleCode="emphasis">www.Salix.com</content>
                     </content>.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold">What are the ingredients in 
OsmoPrep?</content>
                  <paragraph>Active ingredients: sodium phosphate monobasic monohydrate and 
sodium phosphate dibasic anhydrous</paragraph>
                  <paragraph>Inactive ingredients: polyethylene glycol 8000 and magnesium stearate </paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug 
Administration.</paragraph>
                  <paragraph>Revised March 2009</paragraph>
                  <paragraph>Salix Pharmaceuticals, Inc.<br/>Morrisville, NC  27560, USA </paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug 
Administration. </paragraph>
                  <paragraph>VENART-30-4/Mar 2009</paragraph>
               </text>
               <effectiveTime value="20100604"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a407e4f5-7b0e-49f4-9799-1b14e3eb4b02"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="emphasis">OsmoPrep<sup>®</sup>
                        </content>
                     </content>
                     <br/>(sodium phosphate monobasic monohydrate, 
USP <br/>and sodium phosphate dibasic anhydrous, USP) Tablets </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20100604"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM4">
                     <text>image of package label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="package label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>